Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial.

Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, Tow AC, Prince MA, Dermody SS, Jordan R, McKee SA, Fletcher PJ, Claus ED, Klein KR

JAMA network open1 May 2026Cited by 3 (Europe PMC)

PMID42189538PMCIDPMC13213524DOI10.1001/jamanetworkopen.2026.14898PepBankPUB-42189538

Read at source PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults who smoke, the treatment-by-time interaction on laboratory smoking resistance was not significant for semaglutide versus placebo.
In plain wordsIn adults who smoke, semaglutide did not significantly change laboratory smoking resistance compared with placebo over time.
Peptide
Semaglutide
Outcome
No significant changeLaboratory smoking resistance (treatment-by-time interaction)
Study
n = 23
Comparator
Placebo
Analysis
Primary
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 1 week · subcutaneous · 9 weeksAs given in this study (human).
Measurements
Interaction beta
0.16 beta
smoking resistance
Source sentences
Summary
Primary treatment-by-time interactions on laboratory measures of smoking resistance (23 participants; β = 0.16 [95% CI, -0.07 to 0.40]; P = .16)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were non-treatment-seeking adults consuming at least 5 cigarettes per day.
Summary · context
Of 45 participants enrolled, 24 participants (mean [SD] age, 44 [12] years; 20 [83%] female; mean [SD] body mass index, 33.5 [7.2]; mean [SD] cigarettes per day, 15.4 [7.9]) were randomized to placebo (12 participants) or semaglutide (12 participants), of whom 21 participants (88%) completed the pri…
Report a problemFND-4218953801
02HumanRandomized controlled trialEfficacy outcome
In adults who smoke, the treatment-by-time interaction on the number of cigarettes in the laboratory was not significant for semaglutide versus placebo.
In plain wordsIn adults who smoke, semaglutide did not significantly change the number of cigarettes smoked in the laboratory compared with placebo over time.
Peptide
Semaglutide
Outcome
No significant changeLaboratory number of cigarettes (treatment-by-time interaction)
Study
n = 22
Comparator
Placebo
Analysis
Primary
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 1 week · subcutaneous · 9 weeksAs given in this study (human).
Measurements
Interaction beta
−0.08 beta
number of cigarettes
Source sentences
Summary
number of cigarettes (22 participants; β = -0.08 [95% CI, -0.25 to 0.08]; P = .30)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were non-treatment-seeking adults consuming at least 5 cigarettes per day.
Summary · context
Of 45 participants enrolled, 24 participants (mean [SD] age, 44 [12] years; 20 [83%] female; mean [SD] body mass index, 33.5 [7.2]; mean [SD] cigarettes per day, 15.4 [7.9]) were randomized to placebo (12 participants) or semaglutide (12 participants), of whom 21 participants (88%) completed the pri…
Report a problemFND-4218953802
03HumanRandomized controlled trialEfficacy outcome
In adults who smoke, exploratory effect size analyses indicated potential effects of semaglutide on withdrawal symptoms.
In plain wordsIn adults who smoke, an exploratory analysis hinted that semaglutide might affect withdrawal symptoms.
Peptide
Semaglutide
Outcome
Direction not reportedWithdrawal symptoms
Study
n = 24
Comparator
Placebo
Analysis
Exploratory
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 1 week · subcutaneous · 9 weeksAs given in this study (human).
Source sentences
Summary
Exploratory effect size analyses indicated potential effects on withdrawal symptoms.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were non-treatment-seeking adults consuming at least 5 cigarettes per day.
Summary · context
Of 45 participants enrolled, 24 participants (mean [SD] age, 44 [12] years; 20 [83%] female; mean [SD] body mass index, 33.5 [7.2]; mean [SD] cigarettes per day, 15.4 [7.9]) were randomized to placebo (12 participants) or semaglutide (12 participants), of whom 21 participants (88%) completed the pri…
Report a problemFND-4218953807
04HumanRandomized controlled trialEfficacy outcome
In adults who smoke, supplementary change score analyses showed significantly greater reductions in laboratory smoking with semaglutide than with placebo after treatment.
In plain wordsIn adults who smoke, a supplementary analysis showed greater drops in laboratory smoking with semaglutide than with placebo.
Peptide
Semaglutide
Outcome
DecreaseLaboratory smoking (change score analysis)
Study
n = 24
Comparator
Placebo
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 1 week · subcutaneous · 9 weeksAs given in this study (human).
Measurements
beta
−0.69 beta
laboratory smoking
Cohen d
0.67 d
laboratory smoking
Source sentences
Summary
Supplementary change score analyses indicated significantly greater reductions in laboratory smoking (β = -0.69 [95% CI, -1.26 to -0.13]; P = .02; d = 0.67) in the semaglutide group vs the placebo group after treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were non-treatment-seeking adults consuming at least 5 cigarettes per day.
Summary · context
Of 45 participants enrolled, 24 participants (mean [SD] age, 44 [12] years; 20 [83%] female; mean [SD] body mass index, 33.5 [7.2]; mean [SD] cigarettes per day, 15.4 [7.9]) were randomized to placebo (12 participants) or semaglutide (12 participants), of whom 21 participants (88%) completed the pri…
Report a problemFND-4218953803
05HumanRandomized controlled trialEfficacy outcome
In adults who smoke, semaglutide reduced cigarette craving over treatment weeks versus placebo.
In plain wordsIn adults who smoke, semaglutide reduced cigarette craving over the treatment weeks compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseCigarette craving
Study
n = 24
Comparator
Placebo
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 1 week · subcutaneous · 9 weeksAs given in this study (human).
Measurements
Interaction beta
−0.11 beta
craving
Source sentences
Summary
Semaglutide reduced cigarette craving (treatment-by-time interaction: β = -0.11 [95% CI, -0.20 to -0.03]; P = .01)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were non-treatment-seeking adults consuming at least 5 cigarettes per day.
Summary · context
Of 45 participants enrolled, 24 participants (mean [SD] age, 44 [12] years; 20 [83%] female; mean [SD] body mass index, 33.5 [7.2]; mean [SD] cigarettes per day, 15.4 [7.9]) were randomized to placebo (12 participants) or semaglutide (12 participants), of whom 21 participants (88%) completed the pri…
Report a problemFND-4218953804
06HumanRandomized controlled trialEfficacy outcome
In adults who smoke, semaglutide reduced body weight over treatment weeks versus placebo.
In plain wordsIn adults who smoke, semaglutide lowered body weight over the treatment weeks compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseBody weight
Study
n = 24
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 1 week · subcutaneous · 9 weeksAs given in this study (human).
Measurements
Interaction beta
−0.04 beta
body weight
Source sentences
Summary
and body weight (β = -0.04 [95% CI, -0.05 to -0.03]; P < .001)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were non-treatment-seeking adults consuming at least 5 cigarettes per day.
Summary · context
Of 45 participants enrolled, 24 participants (mean [SD] age, 44 [12] years; 20 [83%] female; mean [SD] body mass index, 33.5 [7.2]; mean [SD] cigarettes per day, 15.4 [7.9]) were randomized to placebo (12 participants) or semaglutide (12 participants), of whom 21 participants (88%) completed the pri…
Report a problemFND-4218953805
07HumanRandomized controlled trialEfficacy outcome
In adults who smoke, semaglutide did not significantly reduce weekly cigarettes per day versus placebo.
In plain wordsIn adults who smoke, semaglutide did not significantly reduce cigarettes smoked per day compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeWeekly cigarettes per day
Study
n = 24
Comparator
Placebo
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 1 week · subcutaneous · 9 weeksAs given in this study (human).
Source sentences
Summary
semaglutide monotherapy did not significantly increase laboratory smoking resistance or reduce weekly cigarettes per day
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were non-treatment-seeking adults consuming at least 5 cigarettes per day.
Summary · context
Of 45 participants enrolled, 24 participants (mean [SD] age, 44 [12] years; 20 [83%] female; mean [SD] body mass index, 33.5 [7.2]; mean [SD] cigarettes per day, 15.4 [7.9]) were randomized to placebo (12 participants) or semaglutide (12 participants), of whom 21 participants (88%) completed the pri…
Report a problemFND-4218953806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT05530577

Effects of Semaglutide on Nicotine Intake

University of North Carolina, Chapel Hilln = 247 Oct 2022 to 13 May 2024

Tobacco Use Disorder · Nicotine Addiction

Trial page ClinicalTrials.govUpdated 22 Aug 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.